Real-time Estimate Tradegate 03:04:56 2024-04-26 am EDT 5-day change 1st Jan Change
4.87 EUR +0.62% Intraday chart for VITA 34 AG +10.00% -7.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Vita 34 Starts Patient Enrollment in Phase 1 Trial of CAR-T Drug Candidate MT
Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
VITA 34 AG Provides Revenue Guidance for the Financial Year 2023 CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
VITA 34 AG Revises Earnings Guidance for the Financial Year 2022 CI
VITA 34 AG Announces Dirk Plaga Will Accordingly Assume the Position of Chief Financial Officer of the Company CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022 CI
Vita 34 Names New Chair, Appoints Chief Commercial Officer MT
Vita 34 AG Announces Change in the Chair of the Management Board CI
VITA 34 AG completed the acquisition of Polski Bank Komórek Macierzystych S.A from from AOC Health GmbH, Jakub Baran, Tomasz Baran and others. CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Vita 34 AG Announces Withdrawal of Guidance for Financial Year 2021 CI
Vita 34 : Commences Offer Period for Polski Bank Komorek Takeover MT
VITA 34 AG Affirms Earnings Guidance for the Full Fiscal Year 2021 CI
VITA 34 AG Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Vita 34 : Names New CFO MT
VITA 34 AG Announces Chief Financial Officer Changes CI
VITA 34 AG Provides Earnings Guidance for the Year 2021 CI
Chart VITA 34 AG
More charts
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.84 EUR
Average target price
5.3 EUR
Spread / Average Target
+9.50%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. V3V Stock
  4. News VITA 34 AG
  5. Vita 34 : Commences Offer Period for Polski Bank Komorek Takeover